Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James J Harding

Showing results (41-50 of 138) with videos related to

Pageof 14
Sort By:
BMC Cancer|June 28, 2018
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experienceDanielle C Glassman, Randze L Palmaira, Christina M Covington, et al.
Journal of Vascular and Interventional Radiology : JVIR|March 15, 2025
Outcomes of Transarterial Hepatic Embolization versus Yttrium-90 Radioembolization for Treatment of Patients with Hepatocellular Carcinoma >7 cmSam Y Son, Sara Velayati, Ken Zhao, et al.
Investigational New Drugs|August 4, 2018
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitorJames J Harding, Todd M Bauer, Daniel S W Tan, et al.
Cancer Research Communications|April 11, 2024
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid TumorsBenjamin Garmezy, Mitesh J Borad, Rastilav Bahleda, et al.
Frontiers in Immunology|May 2, 2022
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid TumorsJames J Harding, Ignacio Garrido-Laguna, Xiaoying Chen, et al.
Oncotarget|December 30, 2017
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutationParisa Momtaz, James J Harding, Charlotte Ariyan, et al.
International Journal of Molecular Sciences|December 9, 2023
Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular CarcinomaPerla Chami, Youssef Diab, Danny N Khalil, et al.
Current Oncology (Toronto, Ont.)|May 24, 2024
Outcomes of Y90 Radioembolization for Hepatocellular Carcinoma in Patients Previously Treated with Transarterial EmbolizationKen Zhao, Sam Son, Anita Karimi, et al.
The Journal of Applied Laboratory Medicine|December 19, 2022
Standard Venipuncture vs a Capillary Blood Collection Device for the Prospective Determination of Abnormal Liver ChemistryEnaksha Wickremsinhe, Antoniu Fantana, Erwin Berthier, et al.
Cancer Medicine|August 26, 2020
Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenibImane El Dika, Marinela Capanu, Joanne F Chou, et al.
Pageof 14

Showing results (41-50 of 138) with videos related to

Sort By:
Pageof 14
BMC Cancer|June 28, 2018
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experienceDanielle C Glassman, Randze L Palmaira, Christina M Covington, et al.
Journal of Vascular and Interventional Radiology : JVIR|March 15, 2025
Outcomes of Transarterial Hepatic Embolization versus Yttrium-90 Radioembolization for Treatment of Patients with Hepatocellular Carcinoma >7 cmSam Y Son, Sara Velayati, Ken Zhao, et al.
Investigational New Drugs|August 4, 2018
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitorJames J Harding, Todd M Bauer, Daniel S W Tan, et al.
Cancer Research Communications|April 11, 2024
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid TumorsBenjamin Garmezy, Mitesh J Borad, Rastilav Bahleda, et al.
Frontiers in Immunology|May 2, 2022
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid TumorsJames J Harding, Ignacio Garrido-Laguna, Xiaoying Chen, et al.
Oncotarget|December 30, 2017
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutationParisa Momtaz, James J Harding, Charlotte Ariyan, et al.
International Journal of Molecular Sciences|December 9, 2023
Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular CarcinomaPerla Chami, Youssef Diab, Danny N Khalil, et al.
Current Oncology (Toronto, Ont.)|May 24, 2024
Outcomes of Y90 Radioembolization for Hepatocellular Carcinoma in Patients Previously Treated with Transarterial EmbolizationKen Zhao, Sam Son, Anita Karimi, et al.
The Journal of Applied Laboratory Medicine|December 19, 2022
Standard Venipuncture vs a Capillary Blood Collection Device for the Prospective Determination of Abnormal Liver ChemistryEnaksha Wickremsinhe, Antoniu Fantana, Erwin Berthier, et al.
Cancer Medicine|August 26, 2020
Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenibImane El Dika, Marinela Capanu, Joanne F Chou, et al.
Pageof 14